Recce Ltd has released a press release.
Patients Dosed in R327 Diabetic Foot Infection Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Phase I/II Burn Wound Infection Trial Stage 1 Complete
- Positive Patients Update - Special Access Scheme
- Australian Patent Granted for RECCE Anti-Infectives
- Bonus Canadian R&D Rebate Received
- Scientia Completes Cohort Dosing in Phase I/II UTI Trial
Later from Recce Pharmaceuticals
- Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
- Appendix 4E and Unaudited Preliminary Report
- Additional Positive Patient Cases - Special Access Scheme
- RECCE Trademark Registered - Vietnam
- Opening R&D Address at World AMR Congress
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals